Loading organizations...
§ Private Profile · Menlo Park, CA, USA
Precision diagnostics for early disease detection, specializing in cancer, cardiovascular, and dementia using advanced imaging and AI.
HALO Diagnostics, based in Menlo Park, California, provides precision diagnostics services for early disease detection, focusing on cancer, cardiovascular disease, and dementia. The company integrates advanced imaging, genomics, liquid biomarkers, digital pathology, and AI-driven analytics within its outpatient centers to deliver rapid, actionable results and facilitate minimally invasive treatments. HALO Diagnostics operates by acquiring and upgrading existing imaging centers into comprehensive diagnostic hubs, generating revenue through its precision diagnostic services and strategic partnerships. The company has raised $19 million in Series A funding and currently serves approximately 1 million patients, with plans to triple this volume by 2024. Key personnel include CEO Michael Uhl and Chief Medical Officer Dr. John Feller, while notable investors include Anne Wojcicki, Ronnie Lott, Jim Pallotta, and Fred Moll. Founded in 2019, the company's founders are not publicly known.
HALO Diagnostics has raised $19.0M across 1 funding round.
HALO Diagnostics has raised $19.0M in total across 1 funding round.
HALO Diagnostics has raised $19.0M in total across 1 funding round.
HALO Diagnostics's investors include Zola Global, AYANA Capital LLC, Bain Capital Ventures, TJ Nahigian, Bennu, Bread and Butter Ventures, Commerce Ventures, Cyphr VC, Deep Fork Capital, ENIAC Ventures, Flex Capital, Founders Fund.
HALO Diagnostics has raised $19.0M across 1 funding round. Most recently, it raised $19.0M Series B in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2021 | $19M Series B | Zola Global | Ayana Capital LLC, Bain Capital Ventures, TJ Nahigian, Bennu, Bread And Butter Ventures, Commerce Ventures, Cyphr VC, Deep Fork Capital, Eniac Ventures, Flex Capital, Founders Fund, Foundry Group, High Alpha, Hyde Park Venture Partners, Kleiner Perkins, Matchstick Ventures, Monroe Capital, Mucker Capital, Nyca Partners, RRE Ventures, Sonder Capital, Vayner RSE, Wing Venture Capital, Anne Wojcicki, Baron Davis, Haroon Mokhtarzada, Jason Gardner, Jason Robins, JIM Pallotta, Omar Soliman, Peter Kight, Robert Ciardi, RON Suber, Sébastien Deguy, Tamim Mourad, Warren Jenson, Will Kassoy, Yahya Mokhtarzada | Announced |
HALO Diagnostics (HALO Dx) is a precision diagnostics company founded in 2019, specializing in early detection of major diseases like cancer, cardiovascular disease, and neurodegenerative conditions.[1][2][3] It serves patients and physicians through outpatient centers offering advanced imaging, genomics, non-invasive liquid biomarkers, and AI-driven deep learning algorithms, delivering rapid, actionable results to enable personalized treatments and value-based care.[1][2][3][4] With $19M raised in Series A funding, HALO operates from Menlo Park, California (HQ) and Palm Springs, transforming imaging centers into comprehensive diagnostic hubs serving over one million patients, with plans to triple that by 2024.[1][2][3][6]
The company solves the problem of late-stage disease diagnosis by integrating multimodal data for proactive screening, focusing on the leading causes of ~50% of U.S. deaths, and partnering with providers for minimally invasive therapies like focal laser ablation.[1][3][5][6]
HALO Diagnostics emerged in 2019 from Desert Medical Imaging, a Southern California imaging provider, evolving into a full precision diagnostics platform.[1][5] Key leaders include CEO Michael Uhl (20+ years in tech growth at McKinsey), Chief Medical Officer Dr. John Feller (driving early detection initiatives), and Chief Scientific Officer Thomas P. Slavin, M.D. (triple-board-certified in genetics, molecular diagnostics, and pediatrics).[2][3][5][6]
The idea stemmed from recognizing every patient's uniqueness, combining medical imaging expertise with genomics and AI to shift from reactive to preventive care. Early traction included partnerships like Subtle Medical's AI imaging tech in 2021 for faster, lower-dose scans, and collaborations with CLS for prostate cancer studies using TRANBERG systems, marking pivotal expansion into personalized cancer control.[1][5]
HALO rides the precision medicine wave, leveraging AI, genomics, and multimodal data amid rising demand for early detection amid aging populations and chronic disease burdens causing half of U.S. deaths.[3][4] Timing aligns with post-2020 healthcare shifts toward value-based, outpatient care and AI imaging adoption, amplified by partnerships like CLS for focal therapies and Subtle Medical for efficient scans.[1][5]
Market forces favoring HALO include falling genomics costs, regulatory nods for AI tools, and insurer push for preventive screening to cut late-stage treatment expenses. HALO influences the ecosystem by reskilling imaging centers as diagnostic hubs, scaling access for one million+ patients, and fostering collaborations that validate tech like imILT® for abscopal cancer effects.[1][3][6]
HALO is poised for expansion, tripling its patient base post-2024 via national partner centers and new AI integrations, while extending PathWays to more diseases.[3][6] Trends like AI-driven imaging, liquid biopsies, and personalized oncology will propel growth, especially with Series A momentum and studies proving outcomes in prostate cancer control.[1][5]
Its influence may evolve from regional leader to national precision diagnostics powerhouse, accelerating proactive care and influencing standards in value-based healthcare—reinforcing its core mission to save lives through early, precise detection.[2][3]